Literature DB >> 33725433

Brief High Oxygen Concentration Induces Oxidative Stress in Leukocytes and Platelets: A Randomized Cross-over Pilot Study in Healthy Male Volunteers.

Christina Hafner1, Sibylle Pramhas1, Wolfgang Schaubmayr1, Alice Assinger2, Andreas Gleiss3, Eva Verena Tretter1, Klaus Ulrich Klein1, Gisela Scharbert1.   

Abstract

BACKGROUND: Supplemental oxygen is administered routinely in the clinical setting to relieve or prevent tissue hypoxia, but excessive exposure may induce oxidative damage or disrupt essential homeostatic functions. It is speculated that oxidative stress in leukocytes and platelets may contribute to vascular diseases by promoting inflammation and cell aggregation.
METHODS: In this pilot study 30 healthy male volunteers (18-65 years) were exposed to high oxygen concentration (non-rebreather mask, 8 L/min, 100% O2) and synthetic air (non-rebreather mask, 8 L/min, 21% O2) in a cross-over design for 20 min at a 3-week interval. Venous blood samples were obtained at baseline and 1, 3, and 6 h postintervention. Primary outcome was generation of reactive oxygen species in leukocytes as measured by the redox-sensitive fluorescent dye dihydrorhodamine 123. Additional outcomes were oxidative stress in platelets and platelet aggregation as measured by thromboelastography (ROTEM) and Multiplate analyses.
FINDINGS: High oxygen exposure induced oxidative stress in leukocytes as evidenced by significantly higher mean fluorescence intensity (MFI) compared with synthetic air at 3 h postintervention (47% higher, P = 0.015) and 6 h postintervention (37% higher, P = 0.133). Oxidative stress was also detectable in platelets (33% higher MFI in comparison with synthetic air at 6 h, P = 0.024; MFI 20% above baseline at 3 h, P  = 0.036; 37% above baseline at 6 h, P = 0.002). ROTEM analyses demonstrated reduced mean clotting time 1 h postintervention compared with baseline (-4%, P = 0.049), whereas there were no significant effects on other surrogate coagulation parameters.
CONCLUSION: Clinically relevant oxygen exposure induces oxidative stress in leukocytes and platelets, which may influence the immune and clotting functions of these cells.
Copyright © 2021 by the Shock Society.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33725433     DOI: 10.1097/SHK.0000000000001728

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  5 in total

1.  The Impact of Short-Term Hyperoxia on Cerebral Metabolism: A Systematic Review and Meta-Analysis.

Authors:  Giuseppina Giannì; Andrea Minini; Sara Fratino; Lorenzo Peluso; Filippo Annoni; Mauro Oddo; Sophie Schuind; Jacques Creteur; Fabio Silvio Taccone; Elisa Gouvêa Bogossian
Journal:  Neurocrit Care       Date:  2022-06-01       Impact factor: 3.532

2.  ICONIC study-conservative versus conventional oxygenation targets in intensive care patients: study protocol for a randomized clinical trial.

Authors:  C C A Grim; L I van der Wal; H J F Helmerhorst; D J van Westerloo; P Pelosi; M J Schultz; E de Jonge
Journal:  Trials       Date:  2022-02-13       Impact factor: 2.279

Review 3.  Dangers of hyperoxia.

Authors:  Mervyn Singer; Paul J Young; John G Laffey; Pierre Asfar; Fabio Silvio Taccone; Markus B Skrifvars; Christian S Meyhoff; Peter Radermacher
Journal:  Crit Care       Date:  2021-12-19       Impact factor: 9.097

Review 4.  Optimizing PO2 during peripheral veno-arterial ECMO: a narrative review.

Authors:  Hadrien Winiszewski; Pierre-Grégoire Guinot; Matthieu Schmidt; Guillaume Besch; Gael Piton; Andrea Perrotti; Roberto Lorusso; Antoine Kimmoun; Gilles Capellier
Journal:  Crit Care       Date:  2022-07-26       Impact factor: 19.334

Review 5.  Target arterial PO2 according to the underlying pathology: a mini-review of the available data in mechanically ventilated patients.

Authors:  Julien Demiselle; Enrico Calzia; Clair Hartmann; David Alexander Christian Messerer; Pierre Asfar; Peter Radermacher; Thomas Datzmann
Journal:  Ann Intensive Care       Date:  2021-06-02       Impact factor: 6.925

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.